Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics (CORT)
:CORT
CORT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.84 - $75.00
Previous CloseN/A
Volume78.39K
Average Volume (3M)904.09K
Market Cap
$6.82B
Enterprise Value$4.89B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)50.5
Beta1.01
Next Earnings
Feb 26, 2025EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.26
Shares Outstanding104,775,140
10 Day Avg. Volume884,862
30 Day Avg. Volume904,085
Standard Deviation0.15
R-Squared0.04
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.85
Price to Cash Flow (P/CF)23.10
P/FCF Ratio23.60
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.27
Enterprise Value/Ebitda33.94
Forecast
1Y Price Target
$106.75Price Target Upside68.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe business model remains strong, with Corcept's drug showing consistent growth quarter over quarter for the past two years.
Market OpportunitiesThe CATALYST study found a 24% incidence of hypercortisolism in patients with difficult-to-control type 2 diabetes, suggesting a significant new market opportunity.
Bears Say
Legal ChallengesShares of CORT are down over 6% following news of insurers filing suit against Corcept for blocking generic versions of Korlym.
---
Ownership Overview
15.21% Insiders
17.97% Mutual Funds
16.83% Other Institutional Investors
25.90% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CORT FAQ
What was Corcept Therapeutics’s price range in the past 12 months?
Corcept Therapeutics lowest stock price was $20.84 and its highest was $75.00 in the past 12 months.
What is Corcept Therapeutics’s market cap?
Corcept Therapeutics’s market cap is $6.82B.
When is Corcept Therapeutics’s upcoming earnings report date?
Corcept Therapeutics’s upcoming earnings report date is Feb 26, 2025 which is in 4 days.
How were Corcept Therapeutics’s earnings last quarter?
Corcept Therapeutics released its earnings results on Oct 30, 2024. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.282 by $0.128.
Is Corcept Therapeutics overvalued?
According to Wall Street analysts Corcept Therapeutics’s price is currently Undervalued.
Does Corcept Therapeutics pay dividends?
Corcept Therapeutics does not currently pay dividends.
What is Corcept Therapeutics’s EPS estimate?
Corcept Therapeutics’s EPS estimate is 0.43.
How many shares outstanding does Corcept Therapeutics have?
Corcept Therapeutics has 104,775,140 shares outstanding.
What happened to Corcept Therapeutics’s price movement after its last earnings report?
Corcept Therapeutics reported an EPS of $0.41 in its last earnings report, beating expectations of $0.282. Following the earnings report the stock price went up 4.436%.
Which hedge fund is a major shareholder of Corcept Therapeutics?
Currently, no hedge funds are holding shares in CORT
---
Corcept Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$106.75 (68.00% Upside)
$106.75 (68.00% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 22.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $226.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 7.0%
Last 30 Days ▲ 7.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
193.35%
12-Months-Change
Fundamentals
Return on Equity
25.53%
Trailing 12-Months
Asset Growth
32.02%
Trailing 12-Months
Company Description
Corcept Therapeutics
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
---
CORT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strong positive outlook with significant growth in revenue and promising clinical trial results, particularly for relacorilant. However, there are ongoing legal challenges and some concerns regarding the statistical significance of certain clinical endpoints.Read More>---
CORT Stock 12 Month Forecast
Average Price Target
$106.75
▲(68.00% Upside)
Technical Analysis
Amgen
―
Neurocrine
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
SAGE Therapeutics
―
Best Analysts Covering CORT
1 Year
1 Year Success Rate
11/11 ratings generated profit
1 Year Average Return
+103.16%
reiterated a buy rating 2 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +103.16% per trade.
---